Fu Z, Wang MW, Liu YH, Jiao Y. Impact of immunotherapy on liver metastasis. World J Gastrointest Surg 2024; 16(7): 1969-1972 [PMID: 39087120 DOI: 10.4240/wjgs.v16.i7.1969]
Corresponding Author of This Article
Yan Jiao, MD, PhD, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jul 27, 2024; 16(7): 1969-1972 Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.1969
Impact of immunotherapy on liver metastasis
Zhuo Fu, Ming-Wei Wang, Ya-Hui Liu, Yan Jiao
Zhuo Fu, Medical College, Inner Mongolia Minzu University, Tongliao 028000, Inner Mongolia Autonomous Region, China
Ming-Wei Wang, Ministry of Health Key Laboratory of Radiobiology, School of Public Health of Jilin University, Changchun 130000, Jilin Province, China
Ya-Hui Liu, Yan Jiao, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Jiao Y designed the overall concept and outline of the manuscript; Fu Z contributed to design and the initial draft of the manuscript; Wang MW contributed to the discussion; Liu YH reviewed the literature and revised the manuscript. All authors have read and approved the final manuscript.
Supported byInitiation Project of Science and Technology Department of Inner Mongolia Minzu University, No. KYQD23014.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Jiao, MD, PhD, Surgeon, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Received: March 17, 2024 Revised: May 9, 2024 Accepted: May 28, 2024 Published online: July 27, 2024 Processing time: 126 Days and 23.2 Hours
Abstract
This editorial discusses the article “Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis” published in the latest edition of the World Journal of Gastrointestinal Surgery. Immunotherapy has achieved outstanding success in tumor treatment. However, the presence of liver metastasis (LM) restrains the efficacy of immunotherapy in various tumors, including lung cancer, colorectal cancer, renal cell carcinoma, melanoma, and gastric cancer. A decrease in CD8+ T cells and nature killer cells, along with an increase in macrophages and regulatory T cells, was observed in the microenvironment of LM, leading to immunotherapy resistance. More studies are necessary to determine the best strategy for enhancing the effectiveness of immunotherapy in patients with LM.
Core Tip: The liver is one of the most common sites for tumor metastasis. This editorial reviews the impact of liver metastasis on immunotherapy effectiveness and the possible mechanisms, with an aim to provide new clues for clinical treatment in liver metastatic patients receiving immunotherapy.
